We are studying the effects of DAY101 in children aged 6 months to 25 years with low-grade glioma or advanced solid tumors. The goal is to see if it helps shrink tumors and to assess its safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Malignant glioma is a type of aggressive brain tumor that arises from glial cells, often leading to symptoms such as headaches, seizures, nausea, and neurological deficits. In pediatric patients, it can present as recurrent or progressive low-grade glioma or advanced solid tumors.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
